🚀 go-pugleaf

Dernières parutions d'articles librement accessibles concernant les
cellules souches du cancer du sein:
Most recent free articles on breast cancer stem cells:



Defects in innate immunity render breast cancer initiating cells
permissive to oncolytic adenovirus.
Ahtiainen L, Mirantes C, Jahkola T, Escutenaire S, Diaconu I,
Osterlund P, Kanerva A, Cerullo V, Hemminki A.
PLoS One. 2010 Nov 5;5(11):e13859.
http://www.plosone.org/article/info%3Adoi%2F10.1371%2Fjournal.pone.0013859


Breast cancer stem-like cells are inhibited by a non-toxic aryl
hydrocarbon receptor agonist.
Prud'homme GJ, Glinka Y, Toulina A, Ace O, Subramaniam V, Jothy S.
PLoS One. 2010 Nov 3;5(11):e13831.

http://www.plosone.org/article/info%3Adoi%2F10.1371%2Fjournal.pone.0013831

Increasing CD44+/CD24- tumor stem cells, and upregulation of COX-2 and
HDAC6, as major functions of HER2 in breast tumorigenesis.
Wang KH, Kao AP, Chang CC, Lee JN, Hou MF, Long CY, Chen HS, Tsai EM.
Mol Cancer. 2010 Nov 2;9(1):288.
http://www.molecular-cancer.com/content/9/1/288


Preferential antitumor effect of the Src inhibitor dasatinib
associated with a decreased proportion of aldehyde dehydrogenase 1-
positive cells in breast cancer cells of the basal B subtype.
Kurebayashi J, Kanomata N, Moriya T, Kozuka Y, Watanabe M, Sonoo H.
BMC Cancer. 2010 Oct 20;10:568.
http://www.biomedcentral.com/1471-2407/10/568


The cell-fate determination factor dachshund reprograms breast cancer
stem cell function.
Wu K, Jiao X, Li Z, Katiyar S, Casimiro MC, Yang W, Zhang Q, Willmarth
NE, Chepelev I, Crosariol M, Wei Z, Hu J, Zhao K, Pestell RG.
J Biol Chem. 2010 Oct 11.
http://www.jbc.org/content/early/2010/10/11/jbc.M110.148395.long


Tumor-initiating cells are not enriched in cisplatin-surviving
BRCA1;p53-deficient mammary tumor cells in vivo.
Pajic M, Kersbergen A, van Diepen F, Pfauth A, Jonkers J, Borst P,
Rottenberg S.
Cell Cycle. 2010 Sep;9(18):3780-91.
http://www.landesbioscience.com/journals/cc/article/PajicCC9-18.pdf


Effects of stealth liposomal daunorubicin plus tamoxifen on the breast
cancer and cancer stem cells.
Guo J, Zhou J, Ying X, Men Y, Li RJ, Zhang Y, Du J, Tian W, Yao HJ,
Wang XX, Ju RJ, Lu WL.
J Pharm Pharm Sci. 2010;13(2):136-51.
http://ejournals.library.ualberta.ca/index.php/JPPS/article/viewFile/7548/6685


SLUG/SNAI2 and tumor necrosis factor generate breast cells with CD44+/
CD24- phenotype.
Bhat-Nakshatri P, Appaiah H, Ballas C, Pick-Franke P, Goulet R Jr,
Badve S, Srour EF, Nakshatri H.
BMC Cancer. 2010 Aug 6;10:411.
http://www.biomedcentral.com/1471-2407/10/411


Rb deletion in mouse mammary progenitors induces luminal-B or basal-
like/EMT tumor subtypes depending on p53 status.
Jiang Z, Deng T, Jones R, Li H, Herschkowitz JI, Liu JC, Weigman VJ,
Tsao MS, Lane TF, Perou CM, Zacksenhaus E.
J Clin Invest. 2010 Sep 1;120(9):3296-309.
http://www.jci.org/articles/view/41490















InTextoResearch, Baelen, Liège, Belgique (Belgium) & OncoWal/Wallogene
(Marc Lacroix, scimedweb@mail.com)